apixaban / Generic mfg. - LARVOL DELTA

Rivaroxaban vs. Apixaban in Short bowel syndrome: a focused clinical Pharmacology review. (PubMed, Expert Opin Drug Metab Toxicol) - "Both agents can be effective in selected patients, but apixaban offers greater pharmacokinetic robustness in the context of altered intestinal anatomy or inconsistent oral intake. Early anti-Xa - based monitoring is advisable for either drug to confirm adequate absorption."

Journal • Review • Atrial Fibrillation • Cardiovascular • Gastrointestinal Disorder • Short Bowel Syndrome • Venous Thromboembolism

Early versus delayed DOAC after ischaemic stroke in atrial fibrillation: 1-year outcomes in the TIMING study and in concurrent practice. (PubMed, Eur Stroke J) - "At 1-year follow-up, early initiation of DOAC remained safe and effective with no increase in symptomatic intracerebral haemorrhage. The results support early DOAC initiation in patients with acute ischaemic stroke and atrial fibrillation."

Journal • Atrial Fibrillation • Cardiovascular • Ischemic stroke

Acute coronary syndrome due to intermittent right coronary artery obstruction by an ascending aortic thrombus in a cancer patient: a case report. (PubMed, Eur Heart J Case Rep) - "The patient was discharged on apixaban. This case illustrates dynamic RCA obstruction caused by an aortic root thrombus managed with catheter-based aspiration. However, this approach should be considered on a case-by-case basis, given its high thromboembolic potential."

Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Hematological Disorders • Lung Adenocarcinoma • Lung Cancer • Myocardial Infarction • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombosis

Direct oral anticoagulants are effective in preventing but not resolving radial artery occlusion: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Cardiovasc Med) - "No significant differences were found between groups regarding RAO resolution or the incidence of hematoma, minor bleeding, or major bleeding. https://www.crd.york.ac.uk/prospero/, identifier CRD420251063999."

Journal • Retrospective data • Review • Cardiovascular

An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives. (PubMed, Pharmaceutics) - "Recently, new molecules were authorised to improve patient adherence to treatment, mainly formulated for oral administration (e.g., dabigatran, rivaroxaban, apixaban, etc.)...Also, new anticoagulants for patients with heparin-induced thrombocytopenia (e.g., argatroban, lepirudin, bivalirudin, etc.) were obtained. Moreover, reversal agents for the new anticoagulant molecules used in overdoses or in situations where immediate cessation of the anticoagulant effect is required (e.g., emergency surgery) were studied, some of them being authorised on the pharmaceutical market. This narrative review aims to provide a pharmacological and therapeutic overview of anticoagulant drugs, underlining their implementation and limitations."

Journal • Review • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Oncology • Thrombocytopenia • Thrombosis • Venous Thromboembolism

Ischemic and Bleeding Events After Early Initiation of Direct Oral Anticoagulants for Acute Intracranial Hemorrhage With Non-Valvular Atrial Fibrillation　- A Multicenter Prospective Registry. (PubMed, Circ J) - "In Japanese patients with NVAF, early DOAC (re)initiation ≤14 days after ICH appears to have an acceptable risk for ischemic and hemorrhagic events, particularly in patients with intraparenchymal hemorrhage. In patients with subdural hematoma, early DOAC (re)initiation requires vigilant monitoring."

Journal • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Apixaban Versus Aspirin and Risk of Hemorrhage in the ARCADIA Trial. (PubMed, Ann Neurol) - "We found no increase in any hemorrhage type and a decrease in intracranial hemorrhage with apixaban relative to aspirin in patients with cryptogenic stroke and evidence of atrial cardiopathy. ANN NEUROL 2026."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Thrombosis

Safety and Effectiveness of Apixaban Versus Warfarin in Peritoneal Dialysis Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation (NKF-SCM 2026) - No abstract available

Clinical • Atrial Fibrillation • Cardiovascular

SAFE-HEART: Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR (clinicaltrials.gov) - P3 | N=120 | Not yet recruiting | Sponsor: Meshalkin Research Institute of Pathology of Circulation

New P3 trial • Atrial Fibrillation • Cardiovascular

Factor XI inhibition in atrial fibrillation: where do we stand? (PubMed, G Ital Cardiol (Rome)) - "The phase II AZALEA-TIMI 71 trial was terminated early after showing a significant reduction in the incidence of major bleeding with abelacimab compared with rivaroxaban. In contrast, the phase III OCEANIC-AF trial of asundexian was halted due to inferiority versus apixaban...While FXI inhibitors represent a potential innovation in the treatment of AF, additional evidence is required to clearly and definitively define their role in clinical practice. This review aims to examine the pathophysiological rationale underlying the use of FXI inhibitors, to describe the different molecular subclasses currently under development, and to summarize the results of both completed and ongoing clinical trials of this novel therapeutic class, with the goal of outlining future perspectives for thromboembolic prevention in patients with AF."

Journal • Review • Acute Coronary Syndrome • Atrial Fibrillation • Cardiovascular • Ischemic stroke

The comparison of inflammation markers in patients with non-valvular atrial fibrillation using warfarin and switched to apixaban. (PubMed, Pak J Med Sci) - "Current study results suggested that Apixaban has more effective anti-inflammatory potential compared to Warfarin. The study implicates new perspectives on the anti-inflammatory effects of oral anticoagulants used in the treatment of NVAF."

Journal • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Immunology • Inflammation • Systemic Inflammatory Response Syndrome

MODEL-BASED META-ANALYSIS OF APIXABAN PHARMACOKINETICS IN PEDIATRIC PATIENTS: CLINICAL PRACTICE INSIGHTS (ACC 2026) - "Abstract is embargoed at this time."

PK/PD data • Retrospective data • Pediatrics

SPONTANEOUS RECTUS SHEATH HEMATOMA AND ACUTE LIMB ISCHEMIA IN AN ELDERLY PATIENT ON APIXABAN: A RARE INTERSECTION OF HEMORRHAGIC AND THROMBOTIC COMPLICATIONS (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Cardiovascular • Hematological Disorders

EXTENDED LOW-DOSE APIXABAN AND RISK OF SUPERFICIAL VEIN THROMBOSIS: POST-HOC ANALYSIS OF THE HI-PRO RANDOMIZED TRIAL (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Retrospective data • Cardiovascular • Hematological Disorders • Thrombosis

SAFETY OF APIXABAN IN PEDIATRIC PATIENTS AT HIGH RISK FOR THROMBOEMBOLISM: A BAYESIAN META-ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

Retrospective data • Cardiovascular • Pediatrics

RANDOMIZED TRIAL OF DEFERRED STENTING WITH APIXABAN IN HIGH THROMBUS STEMI USING 3D ECHOCARDIOGRAPHY (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Thrombosis

WHEN ELIQUIS ISN'T ENOUGH: APS-ASSOCIATED LATE TAVR VALVE THROMBOSIS (ACC 2026) - "Abstract is embargoed at this time."

Cardiovascular • Hematological Disorders • Thrombosis

Anticoagulants and pulmonary embolism: the surprising impact of apixaban on bilateral embolism (HEART FAILURE 2026) - No abstract available

Cardiovascular • Pulmonary Embolism

DUAL HYPERSENSITIVITY TO APIXABAN AND RIVAROXABAN IN ATRIAL FLUTTER: BALANCING SAFETY AND CONVENIENCE (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Cardiovascular • Immunology

EFFICACY AND SAFETY OF APIXABAN VERSUS WARFARIN IN LVAD PATIENTS: A PROPENSITY-MATCHED ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

Clinical

INR RARELY >1.5 IN PATIENTS ON APIXABAN: RESULTS FROM THE ARISTOTLE TRIAL (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Cardiovascular

ACTIVATED VS 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATES FOR REVERSAL OF APIXABAN- OR RIVAROXABAN- ASSOCIATED MAJOR BLEEDING (ACC 2026) - "Abstract is embargoed at this time."

APIXABAN VERSUS RIVAROXABAN IN ATRIAL FIBRILLATION PATIENTS RECEIVING CONCOMITANT DILTIAZEM (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Atrial Fibrillation • Cardiovascular

COMPARATIVE SAFETY AND EFFICACY OF LEFT ATRIAL APPENDAGE CLOSURE VERSUS DIRECT ORAL ANTICOAGULANTS (RIVAROXABAN AND APIXABAN) IN ATRIAL FIBRILLATION - A RETROSPECTIVE OBSERVATIONAL STUDY (ACC 2026) - "Abstract is embargoed at this time."

Observational data • Retrospective data • Atrial Fibrillation • Cardiovascular

Scoping review of apixaban and rivaroxaban dosing for atrial fibrillation and venous thromboembolism in advanced chronic kidney disease. (PubMed, Int J Clin Pharm) - "This review summarizes apixaban and rivaroxaban dosing for AF/VTE in advanced CKD, revealing gaps such as limited dose-comparison studies, heterogeneous outcomes and sparse data in non-dialysis. Robust trials are urgently needed."

Journal • Review • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Nephrology • Novel Coronavirus Disease • Renal Disease • Venous Thromboembolism